Solvonis CEO Discusses Progress on Alcohol Use Disorder Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 50 minutes ago
0mins
Source: Yahoo Finance
- Positive PK Data: Solvonis reported encouraging pharmacokinetic (PK) data for its SVN-002 program, demonstrating that sublingual and buccal administration of esketamine provides comparable exposure levels to intranasal delivery, which is crucial for establishing the scientific bridge required by the FDA and accelerating clinical trial progress.
- Significant Market Opportunity: The alcohol use disorder treatment market in the US is estimated to be 4 to 5 times larger than the treatment-resistant depression market currently served by Spravato, with approximately 15 million American adults affected by moderate to severe alcohol use disorder, highlighting Solvonis's innovative potential and market demand in this area.
- Capital Efficiency Strategy: By utilizing the 505(b)(2) regulatory pathway, Solvonis can leverage existing data for a new indication, which not only reduces development costs but also potentially shortens timelines, enhancing the company's financial flexibility and strategic positioning.
- Next Steps: Solvonis plans to engage with the FDA to clarify the scope of the toxicology package and, following feedback, submit an IND application seeking approval for the planned Phase 2b trial, further advancing the clinical development of SVN-002.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 244.880
Low
190.00
Averages
218.50
High
240.00
Current: 244.880
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New Data on IMAAVY in Myasthenia Gravis Treatment
- Clinical Study Results: The Phase 3 Vivacity-MG3 study shows that IMAAVY combined with standard care leads to a significant improvement in MG-ADL scores of -4.9 at 24 weeks compared to -2.7 in the placebo group, indicating its potential advantage in early-stage myasthenia gravis patients.
- Symptom Relief Effect: For patients with lower baseline symptom burden, IMAAVY plus standard care resulted in an MG-ADL score improvement of -4.5 versus -2.3 in the placebo group, further validating its efficacy in milder cases and potentially enhancing treatment options for clinicians.
- Control After Infections: Patients in the IMAAVY group maintained symptom improvements within two weeks after common infections, demonstrating the drug's ability to effectively manage symptoms during periods of heightened exacerbation risk, thus enhancing its clinical applicability.
- Innovative Research Design: The PETUNIA study will showcase how pregnancy outcome data will be collected during IMAAVY treatment, aiming to fill existing evidence gaps and support clinical decision-making, highlighting the focus on pregnant patients.
See More
Solvonis CEO Discusses Progress on Alcohol Use Disorder Treatment
- Positive PK Data: Solvonis reported encouraging pharmacokinetic (PK) data for its SVN-002 program, demonstrating that sublingual and buccal administration of esketamine provides comparable exposure levels to intranasal delivery, which is crucial for establishing the scientific bridge required by the FDA and accelerating clinical trial progress.
- Significant Market Opportunity: The alcohol use disorder treatment market in the US is estimated to be 4 to 5 times larger than the treatment-resistant depression market currently served by Spravato, with approximately 15 million American adults affected by moderate to severe alcohol use disorder, highlighting Solvonis's innovative potential and market demand in this area.
- Capital Efficiency Strategy: By utilizing the 505(b)(2) regulatory pathway, Solvonis can leverage existing data for a new indication, which not only reduces development costs but also potentially shortens timelines, enhancing the company's financial flexibility and strategic positioning.
- Next Steps: Solvonis plans to engage with the FDA to clarify the scope of the toxicology package and, following feedback, submit an IND application seeking approval for the planned Phase 2b trial, further advancing the clinical development of SVN-002.
See More
Choppy Markets as Healthcare Stocks Surge Amid AI Retreat
- Market Volatility: U.S. stocks experienced choppy trading on Friday, with the S&P 500 on track for a nearly 2% drop this week, indicating a soft overall market performance in June that investors should closely monitor for sentiment shifts.
- Oil Price Decline: U.S. benchmark WTI crude is expected to close under $70 per barrel, remaining under pressure despite President Trump's comments on Iran's drone attacks, reflecting a fragile supply-demand dynamic in the oil market.
- Healthcare Sector Surge: The healthcare sector rose over 7% this week, outperforming the S&P 500, with Cardinal Health, Johnson & Johnson, and Eli Lilly poised for record closes on Friday, indicating a renewed investor interest in healthcare amid a retreat from AI stocks.
- Honeywell Spin-off Plan: Honeywell is set to split into two standalone companies, with shareholders receiving one share of Honeywell Aerospace for every two shares owned, and analysts have initiated coverage with a buy rating, anticipating strong growth for the Aerospace division.
See More
Johnson & Johnson Unveils New Data at Neurology Congress
- Research Findings Released: Johnson & Johnson presented 12 abstracts at the 2026 European Academy of Neurology Congress, offering deeper insights into the application of IMAAVY (nipocalimab-aahu) throughout the generalized myasthenia gravis (gMG) treatment journey, highlighting the drug's potential in symptom improvement.
- Clinical Trial Analysis: New analyses from the Phase 3 Vivacity-MG3 study indicate that IMAAVY significantly impacts adults with anti-AChR+ or anti-MuSK+ antibody-positive gMG, particularly in patients early in their disease course and those with lower symptom burden.
- Innovative Study Design: Johnson & Johnson will also showcase the PETUNIA study design, emphasizing the method of collecting pregnancy outcomes data following IMAAVY treatment, reflecting the company's commitment to advancing understanding of gMG management in diverse patient populations.
- Targeted Treatment Significance: As an immunoselective neonatal Fc receptor (FcRn) blocker, IMAAVY aims to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with gMG, underscoring the importance of addressing IgG early in disease progression to enhance treatment efficacy.
See More
Healthcare Sector Outperforms on Wall Street
- Healthcare Stock Performance: Despite year-to-date underperformance, healthcare stocks in the S&P 500 have risen approximately 3%, surpassing the mostly flat benchmark index, indicating resilience and investor confidence in the sector.
- Pharma Giants Reach New Highs: Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck (MRK) have all achieved all-time highs, reflecting market optimism regarding their future growth potential and strategic positioning.
- Biotech Stocks Surge: Companies like Moderna (MRNA), Biogen (BIIB), and Incyte (INCY) have hit 52-week highs, showcasing a rebound in biotech stocks amid rising healthcare M&A activity, which is further boosting the sector's overall performance.
- ETF Performance Highlights: The VanEck Vectors Pharmaceutical ETF (PPH) has posted its fifth consecutive day of gains, demonstrating sustained investor interest in the healthcare sector, particularly in light of the FDA commissioner nominee news, which has positively influenced market sentiment.
See More
Guggenheim Raises Johnson & Johnson Price Target to $270
- Stock Surge: Johnson & Johnson's stock rose 3.4% to $253.18 by midday Friday, reflecting market optimism about its future performance, particularly after the analyst raised the price target to $270, indicating a potential 10.2% upside.
- Earnings Forecast: Guggenheim analyst Vamil Divan predicts that Johnson & Johnson will report approximately $25.5 billion in revenue and $2.87 per share in profits in the upcoming Q2 earnings release, suggesting the company is poised to exceed market expectations in both revenue and earnings, thereby boosting investor confidence.
- Focus Areas: Divan highlighted strong performance in immunology and oncology, particularly with prescriptions for Tremfya exceeding expectations, indicating sustained growth potential in these key areas, which may attract more investor interest.
- Risk Assessment: Despite a strong drug portfolio, Johnson & Johnson's stock trades at over 28 times earnings, with a forecasted single-digit earnings growth rate over the next five years, combined with relatively weak free cash flow, which may lead some investors to adopt a cautious stance on its valuation.
See More
New Data on IMAAVY in Myasthenia Gravis Treatment
- Clinical Study Results: The Phase 3 Vivacity-MG3 study shows that IMAAVY combined with standard care leads to a significant improvement in MG-ADL scores of -4.9 at 24 weeks compared to -2.7 in the placebo group, indicating its potential advantage in early-stage myasthenia gravis patients.
- Symptom Relief Effect: For patients with lower baseline symptom burden, IMAAVY plus standard care resulted in an MG-ADL score improvement of -4.5 versus -2.3 in the placebo group, further validating its efficacy in milder cases and potentially enhancing treatment options for clinicians.
- Control After Infections: Patients in the IMAAVY group maintained symptom improvements within two weeks after common infections, demonstrating the drug's ability to effectively manage symptoms during periods of heightened exacerbation risk, thus enhancing its clinical applicability.
- Innovative Research Design: The PETUNIA study will showcase how pregnancy outcome data will be collected during IMAAVY treatment, aiming to fill existing evidence gaps and support clinical decision-making, highlighting the focus on pregnant patients.
See More
Solvonis CEO Discusses Progress on Alcohol Use Disorder Treatment
- Positive PK Data: Solvonis reported encouraging pharmacokinetic (PK) data for its SVN-002 program, demonstrating that sublingual and buccal administration of esketamine provides comparable exposure levels to intranasal delivery, which is crucial for establishing the scientific bridge required by the FDA and accelerating clinical trial progress.
- Significant Market Opportunity: The alcohol use disorder treatment market in the US is estimated to be 4 to 5 times larger than the treatment-resistant depression market currently served by Spravato, with approximately 15 million American adults affected by moderate to severe alcohol use disorder, highlighting Solvonis's innovative potential and market demand in this area.
- Capital Efficiency Strategy: By utilizing the 505(b)(2) regulatory pathway, Solvonis can leverage existing data for a new indication, which not only reduces development costs but also potentially shortens timelines, enhancing the company's financial flexibility and strategic positioning.
- Next Steps: Solvonis plans to engage with the FDA to clarify the scope of the toxicology package and, following feedback, submit an IND application seeking approval for the planned Phase 2b trial, further advancing the clinical development of SVN-002.
See More
Choppy Markets as Healthcare Stocks Surge Amid AI Retreat
- Market Volatility: U.S. stocks experienced choppy trading on Friday, with the S&P 500 on track for a nearly 2% drop this week, indicating a soft overall market performance in June that investors should closely monitor for sentiment shifts.
- Oil Price Decline: U.S. benchmark WTI crude is expected to close under $70 per barrel, remaining under pressure despite President Trump's comments on Iran's drone attacks, reflecting a fragile supply-demand dynamic in the oil market.
- Healthcare Sector Surge: The healthcare sector rose over 7% this week, outperforming the S&P 500, with Cardinal Health, Johnson & Johnson, and Eli Lilly poised for record closes on Friday, indicating a renewed investor interest in healthcare amid a retreat from AI stocks.
- Honeywell Spin-off Plan: Honeywell is set to split into two standalone companies, with shareholders receiving one share of Honeywell Aerospace for every two shares owned, and analysts have initiated coverage with a buy rating, anticipating strong growth for the Aerospace division.
See More
Johnson & Johnson Unveils New Data at Neurology Congress
- Research Findings Released: Johnson & Johnson presented 12 abstracts at the 2026 European Academy of Neurology Congress, offering deeper insights into the application of IMAAVY (nipocalimab-aahu) throughout the generalized myasthenia gravis (gMG) treatment journey, highlighting the drug's potential in symptom improvement.
- Clinical Trial Analysis: New analyses from the Phase 3 Vivacity-MG3 study indicate that IMAAVY significantly impacts adults with anti-AChR+ or anti-MuSK+ antibody-positive gMG, particularly in patients early in their disease course and those with lower symptom burden.
- Innovative Study Design: Johnson & Johnson will also showcase the PETUNIA study design, emphasizing the method of collecting pregnancy outcomes data following IMAAVY treatment, reflecting the company's commitment to advancing understanding of gMG management in diverse patient populations.
- Targeted Treatment Significance: As an immunoselective neonatal Fc receptor (FcRn) blocker, IMAAVY aims to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with gMG, underscoring the importance of addressing IgG early in disease progression to enhance treatment efficacy.
See More
Healthcare Sector Outperforms on Wall Street
- Healthcare Stock Performance: Despite year-to-date underperformance, healthcare stocks in the S&P 500 have risen approximately 3%, surpassing the mostly flat benchmark index, indicating resilience and investor confidence in the sector.
- Pharma Giants Reach New Highs: Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck (MRK) have all achieved all-time highs, reflecting market optimism regarding their future growth potential and strategic positioning.
- Biotech Stocks Surge: Companies like Moderna (MRNA), Biogen (BIIB), and Incyte (INCY) have hit 52-week highs, showcasing a rebound in biotech stocks amid rising healthcare M&A activity, which is further boosting the sector's overall performance.
- ETF Performance Highlights: The VanEck Vectors Pharmaceutical ETF (PPH) has posted its fifth consecutive day of gains, demonstrating sustained investor interest in the healthcare sector, particularly in light of the FDA commissioner nominee news, which has positively influenced market sentiment.
See More
Guggenheim Raises Johnson & Johnson Price Target to $270
- Stock Surge: Johnson & Johnson's stock rose 3.4% to $253.18 by midday Friday, reflecting market optimism about its future performance, particularly after the analyst raised the price target to $270, indicating a potential 10.2% upside.
- Earnings Forecast: Guggenheim analyst Vamil Divan predicts that Johnson & Johnson will report approximately $25.5 billion in revenue and $2.87 per share in profits in the upcoming Q2 earnings release, suggesting the company is poised to exceed market expectations in both revenue and earnings, thereby boosting investor confidence.
- Focus Areas: Divan highlighted strong performance in immunology and oncology, particularly with prescriptions for Tremfya exceeding expectations, indicating sustained growth potential in these key areas, which may attract more investor interest.
- Risk Assessment: Despite a strong drug portfolio, Johnson & Johnson's stock trades at over 28 times earnings, with a forecasted single-digit earnings growth rate over the next five years, combined with relatively weak free cash flow, which may lead some investors to adopt a cautious stance on its valuation.
See More
